       Document 3095
 DOCN  M94A3095
 TI    alpha 1 Acid glycoprotein as early clinical marker reflecting
       pathophysiological state in SIV infected monkey.
 DT    9412
 AU    Mukai R; Matsui K; Murayama Y; Sata T; Kurata T; Fujii Y; Tamura K;
       Izumi M; Komine K; Takasaka M; et al; Tsukuba Primate Ctr. for Med. Sci.
       NIH, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):155 (abstract no. PB0048). Unique
       Identifier : AIDSLINE ICA10/94369480
 AB    OBJECTIVES: The survival time after SIV inoculation to rhesus monkeys
       varied from animal to animals. We searched for the parameters that could
       predict the fate of the monkeys inoculated with SIV. METHODS: SIVmac
       were inoculated to 8 rhesus and 2 cynomolgus monkeys. Six out of 8
       rhesus macaque died of AIDS, while 2 cynomolgus monkeys still alive.
       Periodical results of serum biochemical analyses, antibody (Ab) titer,
       CD4/CD8 ratio and autopsy were compared in relation to the predictive
       values to the end stage of infected monkeys. RESULTS: Analyses of the
       periodical data of serum biochemical values revealed that elevated alpha
       1 acid glycoprotein (alpha 1-AG) level can predict the end stage of the
       infected monkeys, regardless of their individual symptoms. Moreover, the
       increase in plasma alpha 1-AG was observed as the earliest sign among
       serum protein alterations at the end stage of AIDS monkeys. We also
       found that alpha 1-AG increased immediate after SIV infection prior to
       the raise of the Ab to SIV without exceptions. CONCLUSION: The elevated
       plasma level of alpha 1-AG could be the sign for the successful
       inoculation of SIV in early stage and also be the signal to predict the
       end stage of the SIV infected monkeys.
 DE    Animal  Biological Markers/BLOOD  CD4-CD8 Ratio  Macaca fascicularis
       Macaca mulatta  Orosomucoid/*ANALYSIS  Predictive Value of Tests  Simian
       Acquired Immunodeficiency Syndrome/BLOOD/*PHYSIOPATHOLOGY  *SIV  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

